ITMI20062254A1 - Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca - Google Patents

Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca

Info

Publication number
ITMI20062254A1
ITMI20062254A1 IT002254A ITMI20062254A ITMI20062254A1 IT MI20062254 A1 ITMI20062254 A1 IT MI20062254A1 IT 002254 A IT002254 A IT 002254A IT MI20062254 A ITMI20062254 A IT MI20062254A IT MI20062254 A1 ITMI20062254 A1 IT MI20062254A1
Authority
IT
Italy
Prior art keywords
inzol
methoxy
prepare
pharmaceutical composition
alcanoic acid
Prior art date
Application number
IT002254A
Other languages
English (en)
Italian (it)
Inventor
Giuseppe Biondi
Angelo Guglielminotti
Original Assignee
Acraf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acraf filed Critical Acraf
Priority to IT002254A priority Critical patent/ITMI20062254A1/it
Priority to CA2666371A priority patent/CA2666371C/en
Priority to MX2009004295A priority patent/MX2009004295A/es
Priority to UAA200905093A priority patent/UA97123C2/uk
Priority to DK11185914T priority patent/DK2409698T3/en
Priority to JP2009537517A priority patent/JP5192490B2/ja
Priority to PCT/EP2007/009908 priority patent/WO2008061671A2/en
Priority to PT111859146T priority patent/PT2409698E/pt
Priority to BRPI0718522-7A priority patent/BRPI0718522A2/pt
Priority to SG2011086337A priority patent/SG176508A1/en
Priority to DK07819835.5T priority patent/DK2097080T3/da
Priority to SI200731621T priority patent/SI2409698T1/sl
Priority to EA200970506A priority patent/EA016885B1/ru
Priority to GEAP200711327A priority patent/GEP20125570B/en
Priority to EP11185914.6A priority patent/EP2409698B1/en
Priority to PL11185914T priority patent/PL2409698T3/pl
Priority to ES11185914T priority patent/ES2530623T3/es
Priority to KR1020097010871A priority patent/KR101413616B1/ko
Priority to EP07819835A priority patent/EP2097080B1/en
Priority to US12/444,442 priority patent/US8198310B2/en
Priority to HK09108892.3A priority patent/HK1129071B/en
Priority to SI200731208T priority patent/SI2097080T1/sl
Priority to AU2007323351A priority patent/AU2007323351B2/en
Priority to PT78198355T priority patent/PT2097080E/pt
Priority to PL07819835T priority patent/PL2097080T3/pl
Priority to ES07819835T priority patent/ES2403584T3/es
Priority to CN2007800432200A priority patent/CN101541323B/zh
Priority to ARP070105182A priority patent/AR063894A1/es
Publication of ITMI20062254A1 publication Critical patent/ITMI20062254A1/it
Priority to IL198286A priority patent/IL198286A/en
Priority to US13/466,503 priority patent/US8846745B2/en
Priority to HK12105854.0A priority patent/HK1165275B/en
Priority to CY20151100184T priority patent/CY1116664T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Mixers Of The Rotary Stirring Type (AREA)
IT002254A 2006-11-24 2006-11-24 Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca ITMI20062254A1 (it)

Priority Applications (32)

Application Number Priority Date Filing Date Title
IT002254A ITMI20062254A1 (it) 2006-11-24 2006-11-24 Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca
ES11185914T ES2530623T3 (es) 2006-11-24 2007-11-13 Utilización de un ácido indazolmetoxialcanoico para preparar una composición farmacéutica
PL11185914T PL2409698T3 (pl) 2006-11-24 2007-11-13 Zastosowanie kwasu indazolometoksyalkanowego do wytwarzania kompozycji farmaceutycznej
UAA200905093A UA97123C2 (uk) 2006-11-24 2007-11-13 Застосування індазолметоксиалканової кислоти для зниження рівнів тригліцериду, холестерину та глюкози
DK11185914T DK2409698T3 (en) 2006-11-24 2007-11-13 Use of a indazolmethozyalkanonsyre for the preparation of a pharmaceutical composition
JP2009537517A JP5192490B2 (ja) 2006-11-24 2007-11-13 医薬組成物の調製へのインダゾールメトキシアルカン酸の使用
PCT/EP2007/009908 WO2008061671A2 (en) 2006-11-24 2007-11-13 Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels
PT111859146T PT2409698E (pt) 2006-11-24 2007-11-13 Utilização de um ácido indazol-metoxialcanóico para a preparação de uma composição farmacêutica
BRPI0718522-7A BRPI0718522A2 (pt) 2006-11-24 2007-11-13 Uso de um composto, e, método de tratamento para reduzir os níveis de triglicerídeo, colesterol e/ou glicose no sangue
KR1020097010871A KR101413616B1 (ko) 2006-11-24 2007-11-13 트리글리세라이드, 콜레스테롤 및 글루코스 농도를 낮추기 위한 인다졸메톡시알카노산의 용도
DK07819835.5T DK2097080T3 (da) 2006-11-24 2007-11-13 Anvendelse af en indazolmethoxyalkanonsyre til reduktion af triglycerid-, kolesterol- og glukoseniveauer
SI200731621T SI2409698T1 (sl) 2006-11-24 2007-11-13 Uporaba indazolmetoksialkanojske kisline za pripravo farmacevtskega sestavka
EA200970506A EA016885B1 (ru) 2006-11-24 2007-11-13 Применение индазолметоксиалкановой кислоты для лечения заболевания, связанного с уровнями триглицерида, холестерина и/или глюкозы и способ лечения указанных заболеваний
GEAP200711327A GEP20125570B (en) 2006-11-24 2007-11-13 Use of indazolemethoxyalkanoic acid for reducing levels of triglycerides, cholesterol and glucose
EP11185914.6A EP2409698B1 (en) 2006-11-24 2007-11-13 Use of an indazolemethoxyalkanoic acid to prepare a pharmaceutical composition
CA2666371A CA2666371C (en) 2006-11-24 2007-11-13 Use of an indazolemethoxyalkanoic acid to prepare a pharmaceutical composition
EP07819835A EP2097080B1 (en) 2006-11-24 2007-11-13 Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels
SG2011086337A SG176508A1 (en) 2006-11-24 2007-11-13 Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels
MX2009004295A MX2009004295A (es) 2006-11-24 2007-11-13 Uso de un acido indazolmetoxialcanoico para reducir niveles de triglicerido, colesterol y glucosa.
US12/444,442 US8198310B2 (en) 2006-11-24 2007-11-13 Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels
HK09108892.3A HK1129071B (en) 2006-11-24 2007-11-13 Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels
SI200731208T SI2097080T1 (sl) 2006-11-24 2007-11-13 Uporaba indazolmetoksialkanojske kisline za zniĹľanje nivojev triglicerida, holesterola in glukoze
AU2007323351A AU2007323351B2 (en) 2006-11-24 2007-11-13 Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels
PT78198355T PT2097080E (pt) 2006-11-24 2007-11-13 Utilização de um ácido indazolmetoxialcanóico para a redução dos níveis de triglicéridos, colesterol e glucose
PL07819835T PL2097080T3 (pl) 2006-11-24 2007-11-13 Zastosowanie kwasu indazolometoksyalkanowego do obniżania poziomu triglicerydów, cholesterolu i glukozy
ES07819835T ES2403584T3 (es) 2006-11-24 2007-11-13 Utilización de un ácido indazolmetoxialcanoico para reducir los niveles de triglicéridos, colesterol y glucosa
CN2007800432200A CN101541323B (zh) 2006-11-24 2007-11-13 吲唑甲氧基烷酸用于降低甘油三酯、胆固醇和葡萄糖水平的用途
ARP070105182A AR063894A1 (es) 2006-11-24 2007-11-22 Uso de un acido indazolmetoxialcanoico para preparar una composicion farmaceutica
IL198286A IL198286A (en) 2006-11-24 2009-04-22 Use of alkaneuite indazole acid for the preparation of medical preparations to lower triglyceride, cholesterol and sugar levels
US13/466,503 US8846745B2 (en) 2006-11-24 2012-05-08 Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels
HK12105854.0A HK1165275B (en) 2006-11-24 2012-06-15 Use of an indazolemethoxyalkanoic acid to prepare a pharmaceutical composition
CY20151100184T CY1116664T1 (el) 2006-11-24 2015-02-20 Χρηση ενος ινδαζολο-μεθοξυ-αλκανοϊκου οξεος για την παρασκευη μιας φαρμακευτικης συνθεσης

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT002254A ITMI20062254A1 (it) 2006-11-24 2006-11-24 Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca

Publications (1)

Publication Number Publication Date
ITMI20062254A1 true ITMI20062254A1 (it) 2008-05-25

Family

ID=38198404

Family Applications (1)

Application Number Title Priority Date Filing Date
IT002254A ITMI20062254A1 (it) 2006-11-24 2006-11-24 Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca

Country Status (23)

Country Link
US (2) US8198310B2 (enExample)
EP (2) EP2409698B1 (enExample)
JP (1) JP5192490B2 (enExample)
KR (1) KR101413616B1 (enExample)
CN (1) CN101541323B (enExample)
AR (1) AR063894A1 (enExample)
AU (1) AU2007323351B2 (enExample)
BR (1) BRPI0718522A2 (enExample)
CA (1) CA2666371C (enExample)
CY (1) CY1116664T1 (enExample)
DK (2) DK2097080T3 (enExample)
EA (1) EA016885B1 (enExample)
ES (2) ES2530623T3 (enExample)
GE (1) GEP20125570B (enExample)
IL (1) IL198286A (enExample)
IT (1) ITMI20062254A1 (enExample)
MX (1) MX2009004295A (enExample)
PL (2) PL2097080T3 (enExample)
PT (2) PT2097080E (enExample)
SG (1) SG176508A1 (enExample)
SI (2) SI2409698T1 (enExample)
UA (1) UA97123C2 (enExample)
WO (1) WO2008061671A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20062254A1 (it) 2006-11-24 2008-05-25 Acraf Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca
CN102471282A (zh) 2009-08-03 2012-05-23 方济各安吉利克化学联合股份有限公司 1-苄基-3-羟甲基-1h-吲唑及其衍生物以及所需镁中间体的制备方法
US8999292B2 (en) 2012-05-01 2015-04-07 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
WO2015173786A1 (en) * 2014-05-15 2015-11-19 Boyd Shelley Romayne Compositions and methods for treating and diagnosing ocular disorders
CA3144861A1 (en) 2019-06-25 2020-12-30 Translatum Medicus, Inc. Processes of making 2-((1-benzyl-1h-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives
WO2021263246A1 (en) 2020-06-27 2021-12-30 Crescenta Biosciences Novel cell metabolism modulating compounds and uses thereof
US12138243B2 (en) 2021-12-31 2024-11-12 Crescenta Biosciences Antiviral use of FABP4 modulating compounds

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1131779B (it) * 1980-07-29 1986-06-25 Acraf Sale dell'acido (1-benzil-1h-indazol-3-il)-ossiacetico con la lisina e procedimento per la sua preparazione
IT1230441B (it) * 1989-02-07 1991-10-23 Acraf Eteri della serie dell'indazolo
IT1253703B (it) 1991-04-22 1995-08-23 Angelini Francesco Ist Ricerca Uso di acidi metossi alcanoici dell'indazolo per preparare un farmaco attivo nel trattamento di malattie autoimmunitarie
IT1276031B1 (it) * 1995-10-31 1997-10-24 Angelini Ricerche Spa Composizione farmaceutica per il trattamento delle malattie autoimmuni
US6077539A (en) * 1996-11-12 2000-06-20 Pozen, Inc. Treatment of migraine headache
IT1293795B1 (it) * 1997-07-28 1999-03-10 Angelini Ricerche Spa Farmaco attivo nel ridurre la produzione di proteina mcp-1
IT1293794B1 (it) 1997-07-28 1999-03-10 Acraf Farmaco attivo nel ridurre la produzione di proteina mcp-1
AU766219B2 (en) * 1998-02-02 2003-10-09 1149336 Ontario Inc. Method of regulating glucose metabolism, and reagents related thereto
DE19821625C1 (de) * 1998-05-15 2000-01-05 Merck Patent Gmbh Pharmazeutische Zubereitung
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
ITFI20010230A1 (it) * 2001-11-29 2003-05-29 Menarini Int Operations Lu Sa Composizioni farmaceutiche per il trattamento del diabete mellito di tipo ii
US20060030582A1 (en) * 2002-04-29 2006-02-09 Demartino Julie Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
CA2605900A1 (en) 2005-04-29 2006-11-09 Nycomed Gmbh Mutual prodrug compounds for use as antiinflammatory agents with gastrointestinal protective activity
JP5368801B2 (ja) * 2005-12-01 2013-12-18 フリンダーズ パートナーズ ピーティワイ リミテッド 膵炎を予防および／または治療するための方法および組成物
ITMI20062254A1 (it) 2006-11-24 2008-05-25 Acraf Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca

Also Published As

Publication number Publication date
EP2097080A2 (en) 2009-09-09
EP2409698A1 (en) 2012-01-25
PT2409698E (pt) 2015-02-10
AR063894A1 (es) 2009-02-25
SI2409698T1 (sl) 2015-04-30
SI2097080T1 (sl) 2013-05-31
SG176508A1 (en) 2011-12-29
ES2403584T3 (es) 2013-05-20
IL198286A (en) 2016-03-31
HK1165275A1 (en) 2012-10-05
IL198286A0 (en) 2010-02-17
GEP20125570B (en) 2012-07-10
CY1116664T1 (el) 2017-03-15
WO2008061671A3 (en) 2008-11-27
EP2097080B1 (en) 2013-02-20
WO2008061671A2 (en) 2008-05-29
HK1129071A1 (en) 2009-11-20
US20100069456A1 (en) 2010-03-18
JP2010510263A (ja) 2010-04-02
CA2666371A1 (en) 2008-05-29
US8846745B2 (en) 2014-09-30
US20120283307A1 (en) 2012-11-08
MX2009004295A (es) 2009-05-05
ES2530623T3 (es) 2015-03-04
CN101541323B (zh) 2012-01-04
EA200970506A1 (ru) 2009-10-30
PL2097080T3 (pl) 2013-07-31
PL2409698T3 (pl) 2015-06-30
KR101413616B1 (ko) 2014-07-01
AU2007323351B2 (en) 2013-05-02
DK2409698T3 (en) 2015-04-27
EP2409698B1 (en) 2015-01-21
CN101541323A (zh) 2009-09-23
AU2007323351A1 (en) 2008-05-29
CA2666371C (en) 2014-05-06
US8198310B2 (en) 2012-06-12
UA97123C2 (uk) 2012-01-10
DK2097080T3 (da) 2013-05-21
JP5192490B2 (ja) 2013-05-08
BRPI0718522A2 (pt) 2013-11-12
EA016885B1 (ru) 2012-08-30
KR20090081410A (ko) 2009-07-28
PT2097080E (pt) 2013-04-01

Similar Documents

Publication Publication Date Title
BRPI0816553A2 (pt) "composto, composição farmcêutica, uso de uma composição, uso de um composto, e, processo para a preparação de um composto"
BRPI0810928A2 (pt) "composição farmacêutica"
BRPI0906104A2 (pt) "derivado de ácido nuclêico peptídico, composição farmacêutica contendo uma quantidade "terapeuticamente eficaz do derivado de ácido nuclêico peptídico, composição farmacêutica contendo uma quantidade terapeuticamente eficaz do derivado de ácido nuclêico peptídico,método de utilização do derivado de ácido nuclêico peptídico e composto"
BRPI0818193A2 (pt) composto, sal farmacêuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto
CL2007003609A1 (es) Compuestos derivados de dihidropiridinas sustituidas; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; proceso para producir la composicion farmaceutica; y uso en el tratamiento de una enfermedad mejorada con la inhibicion
DK2068822T3 (da) Selvpræserverede vandige farmaceutiske sammensætninger
CL2007002446A1 (es) Compuestos derivados de morfolino pirimidina; composicion farmaceutica; y su uso para preparar un medicamento para producir un efecto antiproliferante.
DK1984009T3 (da) Farmaceutiske sammensætninger med forbedret stabilitet
BRPI0905680A2 (pt) "composição farmacêutica de uma composição farmacêutica"
BRPI0810161A2 (pt) Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto
BRPI1009392A2 (pt) "formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica."
EP2301525A4 (en) TOPICAL IBUPROFEN FORMULATION
IT1397246B1 (it) Nuovi medicamenti ad uso topico a base di acido ialuronico solfatato come agente attivante o inibente l'attivita' citochinica
FR2917969B1 (fr) Utilisation cosmetique d'un derive d'acide imido-percarboxylique a titre d'agent desquamant
BRPI0716698A2 (pt) Composto, composição farmacêutica e uso de um composto
ITMI20042477A1 (it) Uso di antibiotici a strutura dichetoditiopiperazinica per la preparazione di composizioni farmaceutiche antiangiogeniche
ITRM20080214A1 (it) Derivati dell'acido butirrico somministrabili per via orale, formulazioni che li contengono e loro uso clinico.
SI2409698T1 (sl) Uporaba indazolmetoksialkanojske kisline za pripravo farmacevtskega sestavka
ITMI20040605A1 (it) Esteri butirrici dell'acido ialuronico a basso grado di sostituzione procedimento per la loro preparazione ed uso
DE602004016874D1 (de) Pharmazeutische zusammensetzungen mit malonamid-derivaten zur verringerung der talg-produktion
ITMI20061672A1 (it) Formulazioni di acido acetilsalicilico o suoi derivati in capsule molli,esibenti elevata stabilita'
BRPI0815531A2 (pt) "compostos, composição farmacêutica, composição cosmética, uso cosmético de uma composição e uso de um composto"
BRPI0819038A2 (pt) "uso de uma composição"
IL194094A0 (en) Stable pharmacuetical compositions of 2-aza-bicyclol[3.3.0]-octane-3-carboxylic acid derivatives
BRPI0907664A2 (pt) ''composição farmacêutica anidra, uso de uma composição e processo de preparação de uma composição''